Experimental drug targets Low-Oxygen tumors in prostate cancer

NCT ID NCT06836726

Not yet recruiting Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding evofosfamide to standard hormone therapy can help men with castration-resistant prostate cancer that has spread. The drug targets low-oxygen areas in tumors. 35 participants will receive the drug combination and be monitored for PSA response and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evofosfamide (a drug that targets low-oxygen areas in tumors)
What this could lead to: If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a small, early-phase trial with only 35 participants. The drug may not improve outcomes and could cause side effects like bone marrow suppression or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Princess Margaret Cancer Center

Toronto, Ontario, M7A 2S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.